WisdomTree China ex-State-Owned Enterprises Fund (NASDAQ: CXSE)

에 대한 최신 뉴스 WisdomTree China ex-State-Owned Enterprises Fund (NASDAQ:CXSE)

WisdomTree China ex-State-Owned Enterprises Fund

Consumer Cyclical

Healthcare

Other

Industrials

Communication Services

Financial Services

Technology

Consumer Defensive

Real Estate

Basic Materials

Utilities

Energy

Under normal circumstances, at least 80% of the funds total assets (exclusive of collateral held from securities lending) will be invested in component securities of the index and investments that have economic characteristics that are substantially identical to the economic characteristics of such component securities. The index is a modified float-adjusted market cap weighted index that consists of common stocks in China, excluding common stocks of state-owned enterprises. The fund is non-diversified.

Tencent Holdings Ltd

PDD Holdings Inc

Baidu Inc. Class A

Asia

Large Cap

Emerging Market ETFs

Global

Econ #s

Tech

ETFs

ASHR

BABA

CNYA

CQQQ

CXSE

KWEB

MCHI

PowerShares Golden Dragon Halter USX China Portfolio

TCEHY

최근 몇 주 동안 중국 주식이 부양 정책에 힘입어 급격한 반등을 보였다. iShares MSCI China ETF(NYSE:MCHI)가 추적하는 MSCI China Index는 9월 24일부터 10월 7일 사이에 35% 이상 급등했다.

&#39;빠르고 격렬한 랠리&#39;가 올해 중국 주식을 S&amp;P 500 수익 대비 두 배 상승의 견인

Stifel analyst Rick Wise initiates coverage on Solventum (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SOLV#NYSE">SOLV</a>) with a Buy rating and announces Price Target of $82.

News

Price Target

Initiation

Analyst Ratings

SOLV

Stifel Initiates Coverage On Solventum with Buy Rating, Announces Price Target of $82

Keybanc analyst Sangita Jain maintains Parsons (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PSN#NYSE">PSN</a>) with a Overweight and raises the price target from $99 to $116.

Keybanc Maintains Overweight on Parsons, Raises Price Target to $116

QUIK

QuickLogic's SensiML Partners With Efabless To Empower IoT Innovators With Cost-Effective, Open-Source Edge AI Solutions

Piper Sandler analyst Ryan Todd maintains Phillips 66 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PSX#NYSE">PSX</a>) with a Overweight and raises the price target from $136 to $144.

Piper Sandler Maintains Overweight on Phillips 66, Raises Price Target to $144

Piper Sandler analyst Patrick Moley maintains Virtu Finl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VIRT#NASDAQ">VIRT</a>) with a Overweight and raises the price target from $31 to $35.

VIRT

Piper Sandler Maintains Overweight on Virtu Finl, Raises Price Target to $35

NCNO

nCino To Power Tokushima Taisho Bank's Digital Transformation

Piper Sandler analyst Patrick Moley maintains Tradeweb Markets (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TW#NASDAQ">TW</a>) with a Neutral and raises the price target from $112 to $127.

Piper Sandler Maintains Neutral on Tradeweb Markets, Raises Price Target to $127

Piper Sandler analyst Richard Repetto maintains Nasdaq (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NDAQ#NASDAQ">NDAQ</a>) with a Overweight and raises the price target from $73 to $80.

NDAQ

Piper Sandler Maintains Overweight on Nasdaq, Raises Price Target to $80

Piper Sandler analyst Patrick Moley maintains MarketAxess Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MKTX#NASDAQ">MKTX</a>) with a Neutral and raises the price target from $235 to $265.

MKTX

Piper Sandler Maintains Neutral on MarketAxess Holdings, Raises Price Target to $265

&quot;Topline data from the Phase 1 healthy volunteer study showed good overall tolerability and a pharmacokinetic profile that appears to support tivoxavir&#39;s potential use as a one-time treatment for flu, including pandemic flu. We are especially pleased with data showing that a single dose of tivoxavir maintained plasma drug levels above the EC90&nbsp;for greater than 5 days1,&quot; said&nbsp;Werner Cautreels, PhD, Chief Executive Officer&nbsp;of Traws Pharma.
&quot;With these data, we plan to advance the program to a Phase 2 study in H1 2025.&quot;
At the identified Phase 2 dose, no treatment related adverse events were reported during the Phase 1 study. Topline data from this study showed that a single dose of tivoxavir marboxil maintained plasma drug levels consistently above the EC90&nbsp;for more than five days and within the predicted therapeutic window.
Preclinical studies showed that tivoxavir marboxil demonstrated potent inhibition of drug-resistant influenza viruses, as well as potent inhibition of highly pathogenic bird flu viruses.

TRAW

Traws Pharma Reports Topline Phase 1 Safety And Pharmacokinetic Results For Investigational One-dose Flu Therapy, Tivoxavir Marboxil; Preclinical Data Showed Potent Inhibition Of Drug-resistant And Bird Influenza Viruses

Piper Sandler analyst Patrick Moley maintains Intercontinental Exchange (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ICE#NYSE">ICE</a>) with a Overweight and raises the price target from $170 to $180.

Piper Sandler Maintains Overweight on Intercontinental Exchange, Raises Price Target to $180

Piper Sandler analyst Patrick Moley maintains Interactive Brokers Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBKR#NASDAQ">IBKR</a>) with a Overweight and raises the price target from $140 to $163.

IBKR

Piper Sandler Maintains Overweight on Interactive Brokers Gr, Raises Price Target to $163

Piper Sandler analyst Patrick Moley maintains CME Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CME#NASDAQ">CME</a>) with a Overweight and raises the price target from $225 to $240.

Piper Sandler Maintains Overweight on CME Gr, Raises Price Target to $240

MYND

Mynd.ai Sells Non-Strategic Unit For $20M, Implements Strategic Actions To Boost Operations And Shareholder Value

ZenaTech, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZENA#NASDAQ">ZENA</a>) ("ZenaTech"), a technology company specializing in AI (Artificial Intelligence) drone solutions and enterprise SaaS (Software-as-a-Service) solutions, today announced that its subsidiary, ZenaDrone, has commenced aerial operations to launch commercial drone services in the US. This was made possible due to recently achieving Federal Aviation Authority (FAA) exemption approval.
ZenaDrone will be setting up <a href="https://www.globenewswire.com/Tracker?data=lb-jSJYJE5oFsgWG9zF_EP4wo9a8Tna77LodRA59TLtXz9aIQJu6THiHPG4coWFjkSrEv2mQdRyvLXDtSYgRn5kB7KOgLhuE4GQnnMi-z50=">Drone-as-a-Service</a> (DaaS) operations, initially through its Phoenix, Arizona office, making its drone hardware and software solutions available to customers for use in land surveying, inspection, monitoring, tracking, and other applications using the ZenaDrone 1000 product. As part of these operations, the company will be building up flight hours and airworthiness accreditation required for full commercial operations.
The Company is currently completing the FAA application process to receive an aerial spraying license (14 CFR Part 137) to use ZenaDrone 1000 for plant nourishment, soil treatment, and pest control purposes in agriculture settings.
"After over a year and a half of application submission and approval timelines, and preparation to ensure we can operate in compliance with FAA requirements, we are excited to be able to commence operations for commercial services and revenue generation in the US," said CEO Dr. Shaun Passley, Ph.D. "We are hopeful this work will pave the way for similar regulatory approvals in additional countries where we've applied and seek to operate in the future."
The company previously announced that ZenaDrone had been granted an exemption by the FAA for visual line-of-sight commercial applications and data collection in the US, subject to specified conditions and limitations. This approval enables live testing, evaluation, and demonstration of ZenaDrone 1000 with US-based customers and partners. The company will begin testing for beyond visual line-of-sight (BVLOS) use at an overseas location in the next few months.
The ZenaDrone 1000 is an <a href="https://www.globenewswire.com/Tracker?data=DZCVB_iq3KFFFJ8uNbKot0zMjqcDx1qqN3cgPGwESrHCiiw214u0UKWaEZHAE7Rs6zuV8m0sVRn30wjCJuL4Io7R_hwH8nE1TVqKCnOJFa4=">autonomous drone</a> product designed for stable flight, maneuverability, heavy lift capabilities, incorporating innovative software technology, AI, sensors, and purpose-built attachments, along with compact and rugged hardware engineered for industrial use. It has been used in the agriculture sector enabling smart farming, plant tracking, and crop management. ZenaDrone's products have also been piloted in the field with the US military for delivery of temperature-controlled critical medical supplies.

Government

Regulations

ZENA

ZenaTech's ZenaDrone Launches Commercial Drone Services in the US for Agriculture and Industry After FAA Approval

Porsche is recalling 27,527 <a href="https://www.benzinga.com/news/24/06/39477997/porsche-recalls-nearly-32-000-taycan-evs-in-us-over-braking-performance-concerns">Taycan EVs</a> in the U.S. owing to concerns of the high-voltage battery experiencing a short circuit within the battery module, the National Highway Traffic Safety Administration (NHTSA) said on Tuesday.
What Happened: The recall population includes model year 2021-2024 Taycan sportscars. The short circuit, the auto safety regulator said, can increase the risk of a thermal event and even fires.
While some vehicle owners will be notified to not charge their vehicles beyond 80% as an interim remedy, some customers with vehicles that allow Porsche to continuously monitor the high-voltage battery data and identify anomalies with the help of data analytics will not have to cater to the same demand, NHTSA said. 
Final Fix: All recall-affected vehicles, however, will have the high-voltage battery modules analyzed. If an anomaly is identified, the affected modules will be replaced and an on-board diagnostic software will be installed to detect future battery module anomalies by the first quarter of 2025, the regulator said.
The diagnostic software will help identify future anomalies in high-voltage battery modules and display warning messages in the head unit in case of an anomaly. It will also limit the battery&#8217;s charging capacity until the affected battery modules are replaced, <a href="https://www.benzinga.com/news/24/06/39477997/porsche-recalls-nearly-32-000-taycan-evs-in-us-over-braking-performance-concerns">the regulator said</a>. 
The Taycan is one of the pricier EVs in the U.S. market with a starting price of about $100,000. The premium sports sedan is also Porsche's first production EV. 
Check out more of Benzinga&#8217;s Future Of Mobility coverage by&nbsp;<a href="https://www.benzinga.com/topic/mobility" target="_blank" rel="noreferrer noopener">following this link</a>.
Read More:
<ul>
<li><a href="https://www.benzinga.com/news/24/10/41220996/teslas-former-head-of-vehicle-programs-who-left-on-the-heels-of-mass-layoff-joins-waymo" target="_blank" rel="noreferrer noopener">Tesla&#8217;s Former Head Of Vehicle Programs Who Left On The Heels Of Mass Layoff Joins Waymo</a></li>
</ul>
Photo courtesy: Porsche

Porsche Recalls Over 27K Taycan EVs In US Citing Concerns Of Short Circuit Within Battery Module

This collaboration will leverage Autonomous&#39; precision encrypted RNA&nbsp;(encRNA) technology and MiNK&#39;s iNKT cell therapies, MiNK-215 and agenT-797.&nbsp;The companies will evaluate these technologies in state-of-the-art metastatic solid tumor models.
Based on the results, the companies plan to launch a Phase 1 clinical trial in patients with treatment-refractory metastatic solid tumors, including microsatellite stable (MSS) colorectal cancers.

INKT

MiNK Therapeutics, Autonomous Therapeutics Enter Research Collaboration Aimed At Effectively Targeting And Treating Metastatic Tumors

Vivos Therapeutics, Inc. ("Vivos" or the "Company") (NASDAQ:<a href="https://www.benzinga.com/stock/VVOS#NASDAQ">VVOS</a>), a medical technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep-related breathing disorders, including obstructive sleep apnea (OSA) in adults and children, today announced the American Medical Association (AMA) has issued new CPT&#xAE; medical codes applicable to all Vivos CARE oral medical devices, which will become effective January 1, 2025. &nbsp;
Vivos Chairman and CEO, Kirk Huntsman, stated, "This is exciting news for OSA patients and medical providers who treat sleep breathing disorders. Our CARE oral medical devices are the only ones cleared by the U.S. Food and Drug Administration for the treatment of moderate to severe OSA, and these new medical codes will now facilitate coverage and reimbursement by commercial medical insurance payers. From Vivos' perspective, we believe this will enable a larger number of patients from most demographics to access our breakthrough, proprietary airway remodeling technology and more effectively treat their OSA. This development comes at an opportune moment for Vivos as our recent regulatory approvals, coupled with our new alliance-based marketing and distribution model and now these new codes put Vivos in an improved position to drive revenue growth."
AMA Introduces 420 Updates in CPT&#xAE; 2025, Including New Codes for Vivos
In a recent press release, the AMA explained, "The emergence of medical innovations, new technologies and cutting-edge procedures spurred most of the annual changes presented in the release of the&nbsp;<a href="https://www.globenewswire.com/Tracker?data=rmauKNBxXv8VAtx_L-ayHzPsOR_nzmXHSycfk5xj0jpYn5vkEriXHUJycJWcVWmNiI3LGrxf3EYUWfMqahZynbuA5cAOE6SMFfuzdwS_yq5hQAL_C02gLrTLuu9ndvY4rKjVFdd2GlW-rPufO1yc8irvEoGztAJF7CKvFGupjAw=">Current Procedural Terminology</a>&nbsp;(CPT&#xAE;) 2025, the nation's uniform data-sharing code set for medical procedures and services. There are 420 overall updates in the CPT&#xAE; 2025 code set, including 270 new codes, 112 deletions, and 38 revisions."&nbsp;
"The CPT&#xAE; code set is the foundation for the efficient and effective exchange of standardized information in a data-driven health system…with the goal of delivering better patient care, improved outcomes and lower costs," said AMA President Bruce A, Scott, M.D. "The latest updates to the CPT&#xAE; code set reflect advancements in contemporary clinical practice."
Mr. Huntsman concluded, "This AMA approval represents our latest regulatory and reimbursement milestone, following another important approval Vivos received for Medicare coverage just a few months ago. As part of our mission, Vivos has worked to make its innovative OSA treatment protocols available to more people so they can improve their lives. With these new CPT&#xAE; codes, we are taking a major step towards making OSA treatment more accessible and affordable for patients nationwide, including children ages 6 to 17. This approval highlights our commitment to ensuring more people can receive the care they need while receiving greater support from their healthcare insurance plans."

VVOS

Vivos Therapeutics Gains AMA Approval for New Medical Codes, Expanding Access to Sleep Apnea Treatment

Keybanc analyst Sangita Jain maintains Tetra Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTEK#NASDAQ">TTEK</a>) with a Overweight and raises the price target from $49 to $56.

TTEK

Keybanc Maintains Overweight on Tetra Tech, Raises Price Target to $56

The contract was executed in response to a request from the Ministry of Health in Morocco to make the therapy available in the country and help prepare and protect its citizens against any potential mpox outbreak.
Tecovirimat is approved in the U.S., Canada, and the EU, and while it has also been available in Africa through clinical trials and as part of the World Health Organization&#39;s emergency use access protocol, this agreement marks SIGA&#39;s first commercial sale of TPOXX on the continent.

Comments

WisdomTree China ex-State-Owned Enterprises Fund

뉴스

에 대한 최신 뉴스 WisdomTree China ex-State-Owned Enterprises Fund (NASDAQ:CXSE)

화요일, 10월 08, 2024

뉴스

파트너 / 기고자

벤징가 글로벌